|
GPBP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
2.26160201677317E-11 |
| Normal-vs-Stage3 |
4.9960036108132E-15 |
| Normal-vs-Stage4 |
5.55111512312578E-15 |
| Stage1-vs-Stage2 |
4.566600E-01 |
| Stage1-vs-Stage3 |
1.843640E-01 |
| Stage1-vs-Stage4 |
1.607770E-02 |
| Stage2-vs-Stage3 |
8.154200E-01 |
| Stage2-vs-Stage4 |
2.790800E-01 |
| Stage3-vs-Stage4 |
3.379600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.96199999999725E-06 |
| Normal-vs-Asian |
6.51849685340267E-11 |
| Caucasian-vs-AfricanAmerican |
2.506200E-01 |
| Caucasian-vs-Asian |
3.580000E-01 |
| AfricanAmerican-vs-Asian |
5.535000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.38777878078145E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.383400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63957736276643E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
7.414200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.843580E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.051740E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.446200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.588610E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.226400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.226400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.31339999999802E-05 |
| Classical-VS-Follicular |
6.671700E-02 |
| Classical-VS-Other |
7.047400E-01 |
| Classical-VS-Normal |
4.40150138558693E-11 |
| Tall-VS-Follicular |
3.568400E-02 |
| Tall-VS-Other |
1.016200E-01 |
| Tall-VS-Normal |
1.4432899320127E-15 |
| Follicular-VS-Other |
7.864800E-01 |
| Follicular-VS-Normal |
2.19224638442483E-12 |
| Other-VS-Normal |
1.558850E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22044604925031E-16 |
| Normal-vs-N1 |
2.22044604925031E-14 |
| N0-vs-N1 |
1.405000E-01 |
|
|
